Roche’s High Stakes Gambit For Genentech
Executive Summary
With Roche's unsolicited attempt to buy out Genentech's minority shareholders for $89 dollars a share, a bid totaling nearly $44 billion, the company is wagering heavily that it will not destroy one of the industry's most successful pharma-biotech collaborations. But has Roche laid out a straight flush or lost its ace to a bluff
You may also be interested in...
Clinical Development Setbacks, Pricing Pressures Hit Roche
Recent setbacks for two of its most important pipeline projects, as well as a tougher pricing environment in key Western countries, will take a toll on Roche in 2010 and beyond, company executives told analysts during a half-year earnings call on July 22
Clinical Development Setbacks, Pricing Pressures Hit Roche
Recent setbacks for two of its most important pipeline projects, as well as a tougher pricing environment in key Western countries, will take a toll on Roche in 2010 and beyond, company executives told analysts during a half-year earnings call on July 22
Clinical Development Setbacks, Pricing Pressures Hit Top, Bottom Lines at Roche
"The financial crisis has arrived for the pharmaceutical industry," says CEO Severin Schwan.